The sixth edition of EvaluatePharma's World Preview brings together many of our analyses to provide a top level insight, from the world's financial market, into the expected performance of the industry between now and 2018. 

Based on EvaluatePharma's coverage of the world's leading 4,000 pharmaceutical and biotech companies, the World Preview highlights trends in prescription drug sales, patent risk, R&D spend, global brand sales and market performance by therapy area. Also included in the report is a brief review of 2012 performance - view the report infographic (PDF).

Key highlights in the World Preview 2013, Outlook to 2018 include:

  • Worldwide prescription drug sales forecast to total $895bn in 2018 (CAGR: 3.8% between 2012 and 2018)
  • In dollar terms, worldwide prescription drugs sales experienced an unprecedented fall of 1.6% in 2012 due to a large number of blockbuster patent expiries
  • Between 2013 and 2018, $230bn of sales at risk from patent expiration
  • Humira projected to be world's largest selling product in 2018
  • Pfizer remains top company by worldwide Rx sales in 2012; Novartis number two
  • By 2018, Novartis expected to be number one, in terms of worldwide Rx sales
  • Worldwide pharmaceutical R&D spend forecast to be $149bn in 2018 (CAGR: 1.4% between 2012 and 2018)

Every year we publish our 44+ page World Preview report and make it available to industry free of charge. 

To download you own complimentary copy of the latest edition, we only ask that you confirm your details on the short form opposite so that we may better understand our growing readership. Many thanks. 

World Preview 2013, Outlook to 2018

Returning to Growth